Skip to main content
Premium Trial:

Request an Annual Quote

RxGen Opens Toxicology Subsidiary, Names Unit CEO

NEW YORK, Jan. 26 (GenomeWeb News) - RxGen today said it has created RxGen PrimaTox, a wholly owned subsidiary focused on drug-safety products and services.


RxP is developing drug safety biomarkers using "tox-omics" tools and will provide these as stand-alone products. It is also building a primate-based molecular toxicology database to be available on a subscription basis, the company said.


Spencer Farr, founder of Xenometrix and Phase-1 Toxicology, was named CEO of the new unit.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.